
Opinion|Videos|March 27, 2025
Monitoring Strategies for Managing ADC Toxicities in mBC
Panelists discuss how pharmacists should monitor neutropenia, diarrhea, and mucositis from sacituzumab govitecan (SG); interstitial lung disease (ILD) and neutropenia from trastuzumab deruxtecan (T-DXd); and neutropenia and ILD from datopotamab deruxtecan (Dato-DXd). Proactive management is essential for patient safety.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- Toxicity management is critical for patients on antibody-drug conjugates (ADCs). What are the most important ADC-related AEs that pharmacists should monitor (eg, neutropenia, diarrhea, ILD, mucositis) for T-DXd, SG, and Dato-DXd?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Biosimilar Stivant Shows Noninferior Efficacy and Comparable Safety to Reference Bevacizumab
3
Under Pressure: A Brief Overview of the Updated Hypertension Guidelines
4
Current and Emerging BCMAxCD3 Bispecifics
5